 Natalie Nokoff
Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transgender Persons | 15 | 2026 | 207 | 5.340 |
Why?
| | Adrenal Hyperplasia, Congenital | 13 | 2026 | 39 | 5.150 |
Why?
| | Disorders of Sex Development | 12 | 2025 | 40 | 2.930 |
Why?
| | Testosterone | 12 | 2026 | 412 | 2.350 |
Why?
| | Athletic Performance | 4 | 2026 | 78 | 1.730 |
Why?
| | Gender Dysphoria | 5 | 2024 | 19 | 1.250 |
Why?
| | Estradiol | 6 | 2026 | 507 | 1.200 |
Why?
| | Gonadotropin-Releasing Hormone | 3 | 2024 | 212 | 1.110 |
Why?
| | Mental Disorders | 5 | 2025 | 1154 | 1.050 |
Why?
| | Glucocorticoids | 3 | 2026 | 528 | 1.020 |
Why?
| | Neurodevelopmental Disorders | 4 | 2025 | 223 | 1.020 |
Why?
| | Insulin Resistance | 4 | 2026 | 1241 | 0.990 |
Why?
| | Cardiovascular Diseases | 4 | 2025 | 2172 | 0.970 |
Why?
| | Sports | 2 | 2026 | 215 | 0.920 |
Why?
| | Sex Determination Analysis | 1 | 2025 | 9 | 0.890 |
Why?
| | Androgen Antagonists | 1 | 2025 | 92 | 0.830 |
Why?
| | Cardiorespiratory Fitness | 1 | 2024 | 74 | 0.820 |
Why?
| | Gonadal Steroid Hormones | 3 | 2024 | 143 | 0.790 |
Why?
| | Genitalia | 6 | 2021 | 34 | 0.780 |
Why?
| | Puberty | 3 | 2024 | 135 | 0.780 |
Why?
| | Turner Syndrome | 5 | 2025 | 64 | 0.760 |
Why?
| | Kidney | 4 | 2025 | 1495 | 0.750 |
Why?
| | Glomerular Filtration Rate | 3 | 2025 | 764 | 0.750 |
Why?
| | Adolescent | 29 | 2026 | 22409 | 0.710 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 657 | 0.690 |
Why?
| | Adrenal Insufficiency | 2 | 2021 | 28 | 0.670 |
Why?
| | Genital Diseases, Female | 2 | 2021 | 31 | 0.660 |
Why?
| | Male | 52 | 2026 | 72431 | 0.650 |
Why?
| | Female | 58 | 2026 | 78304 | 0.640 |
Why?
| | Child | 32 | 2026 | 22600 | 0.640 |
Why?
| | Mood Disorders | 1 | 2021 | 140 | 0.640 |
Why?
| | Body Composition | 2 | 2020 | 689 | 0.580 |
Why?
| | Klinefelter Syndrome | 3 | 2025 | 69 | 0.580 |
Why?
| | Urogenital Surgical Procedures | 3 | 2020 | 5 | 0.570 |
Why?
| | Caregivers | 5 | 2022 | 1062 | 0.570 |
Why?
| | Parents | 8 | 2022 | 1395 | 0.550 |
Why?
| | Humans | 68 | 2026 | 144667 | 0.550 |
Why?
| | Anxiety | 4 | 2023 | 1122 | 0.540 |
Why?
| | Child, Preschool | 17 | 2026 | 11790 | 0.540 |
Why?
| | Emergency Service, Hospital | 2 | 2024 | 2325 | 0.530 |
Why?
| | Hypertension | 2 | 2022 | 1262 | 0.500 |
Why?
| | Amines | 3 | 2026 | 39 | 0.490 |
Why?
| | Genital Diseases, Male | 1 | 2016 | 16 | 0.490 |
Why?
| | Athletes | 3 | 2026 | 421 | 0.490 |
Why?
| | Thiazoles | 3 | 2026 | 139 | 0.470 |
Why?
| | Biomarkers | 4 | 2025 | 4261 | 0.470 |
Why?
| | Case-Control Studies | 5 | 2025 | 3603 | 0.450 |
Why?
| | Androgens | 2 | 2026 | 178 | 0.390 |
Why?
| | Patient Acceptance of Health Care | 2 | 2025 | 881 | 0.390 |
Why?
| | Emergencies | 1 | 2014 | 175 | 0.370 |
Why?
| | Body Mass Index | 2 | 2025 | 2419 | 0.370 |
Why?
| | Electronic Health Records | 4 | 2025 | 1176 | 0.360 |
Why?
| | Ambulatory Care Facilities | 1 | 2014 | 267 | 0.340 |
Why?
| | Cross-Sectional Studies | 5 | 2025 | 5870 | 0.330 |
Why?
| | Sex Characteristics | 5 | 2024 | 776 | 0.330 |
Why?
| | Acute Disease | 1 | 2014 | 1029 | 0.330 |
Why?
| | Infant | 12 | 2025 | 10023 | 0.320 |
Why?
| | Obesity | 3 | 2022 | 3070 | 0.320 |
Why?
| | Sexual Development | 6 | 2023 | 17 | 0.320 |
Why?
| | Autism Spectrum Disorder | 3 | 2025 | 410 | 0.310 |
Why?
| | Propensity Score | 2 | 2021 | 373 | 0.300 |
Why?
| | Odds Ratio | 2 | 2021 | 1076 | 0.280 |
Why?
| | Insulin | 1 | 2019 | 2502 | 0.280 |
Why?
| | Androstenedione | 2 | 2024 | 10 | 0.260 |
Why?
| | Gender Identity | 4 | 2024 | 126 | 0.250 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2350 | 0.240 |
Why?
| | Testosterone Congeners | 2 | 2023 | 7 | 0.240 |
Why?
| | Logistic Models | 2 | 2021 | 2114 | 0.240 |
Why?
| | Growth Charts | 1 | 2025 | 20 | 0.230 |
Why?
| | Autoimmunity | 1 | 2012 | 930 | 0.230 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2025 | 33 | 0.230 |
Why?
| | Prospective Studies | 7 | 2026 | 7994 | 0.230 |
Why?
| | Pediatrics | 1 | 2014 | 1121 | 0.230 |
Why?
| | Hormone Replacement Therapy | 1 | 2026 | 107 | 0.220 |
Why?
| | Longitudinal Studies | 5 | 2024 | 2942 | 0.220 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2013 | 3910 | 0.220 |
Why?
| | Quality of Life | 7 | 2021 | 3183 | 0.220 |
Why?
| | Mineralocorticoids | 1 | 2025 | 7 | 0.220 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1406 | 0.220 |
Why?
| | Sex Chromosome Aberrations | 2 | 2025 | 69 | 0.210 |
Why?
| | Sex Chromosome Disorders | 1 | 2025 | 27 | 0.210 |
Why?
| | Contraceptive Agents, Female | 1 | 2025 | 80 | 0.210 |
Why?
| | Body Height | 1 | 2025 | 199 | 0.210 |
Why?
| | Infant, Newborn | 4 | 2025 | 6399 | 0.210 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2024 | 6 | 0.210 |
Why?
| | Blood Proteins | 1 | 2026 | 230 | 0.210 |
Why?
| | Hypophosphatemia | 1 | 2024 | 17 | 0.210 |
Why?
| | Trisomy | 1 | 2025 | 78 | 0.200 |
Why?
| | Genitalia, Female | 2 | 2021 | 42 | 0.200 |
Why?
| | Endometriosis | 1 | 2024 | 57 | 0.200 |
Why?
| | Contraception | 1 | 2025 | 170 | 0.200 |
Why?
| | Primary Health Care | 1 | 2014 | 1730 | 0.190 |
Why?
| | Neonatal Screening | 1 | 2025 | 179 | 0.190 |
Why?
| | Leuprolide | 1 | 2022 | 21 | 0.190 |
Why?
| | Risk Factors | 5 | 2021 | 10796 | 0.190 |
Why?
| | Uncertainty | 2 | 2020 | 145 | 0.180 |
Why?
| | Sports Medicine | 1 | 2023 | 119 | 0.170 |
Why?
| | Oxygen Consumption | 1 | 2024 | 717 | 0.170 |
Why?
| | Wnt4 Protein | 1 | 2021 | 20 | 0.170 |
Why?
| | Health Status Disparities | 1 | 2024 | 318 | 0.170 |
Why?
| | Young Adult | 7 | 2025 | 14122 | 0.170 |
Why?
| | Monosomy | 1 | 2021 | 10 | 0.170 |
Why?
| | Proteome | 1 | 2026 | 515 | 0.170 |
Why?
| | Overweight | 2 | 2022 | 606 | 0.160 |
Why?
| | Cardiology | 1 | 2024 | 359 | 0.160 |
Why?
| | Adaptation, Psychological | 2 | 2016 | 718 | 0.160 |
Why?
| | Child Behavior Disorders | 1 | 2021 | 118 | 0.160 |
Why?
| | Dyslipidemias | 1 | 2022 | 182 | 0.160 |
Why?
| | Decision Making | 3 | 2022 | 973 | 0.160 |
Why?
| | Adult | 13 | 2026 | 40489 | 0.150 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2019 | 50 | 0.150 |
Why?
| | Sexual Maturation | 1 | 2019 | 48 | 0.150 |
Why?
| | Growth Hormone | 1 | 2019 | 91 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 118 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.150 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 889 | 0.150 |
Why?
| | Liver Diseases | 1 | 2022 | 304 | 0.150 |
Why?
| | Vascular Malformations | 1 | 2019 | 50 | 0.150 |
Why?
| | Women's Health | 1 | 2021 | 307 | 0.140 |
Why?
| | Postmenopause | 1 | 2021 | 390 | 0.140 |
Why?
| | Capillaries | 1 | 2019 | 118 | 0.140 |
Why?
| | Reproductive Health | 1 | 2019 | 90 | 0.140 |
Why?
| | Phosphoproteins | 1 | 2021 | 339 | 0.140 |
Why?
| | Suicidal Ideation | 1 | 2024 | 575 | 0.140 |
Why?
| | Developmental Disabilities | 1 | 2021 | 279 | 0.140 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2021 | 180 | 0.140 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2021 | 194 | 0.140 |
Why?
| | Mentors | 1 | 2020 | 214 | 0.130 |
Why?
| | Sex Factors | 2 | 2024 | 2104 | 0.130 |
Why?
| | Stress, Psychological | 3 | 2026 | 1148 | 0.130 |
Why?
| | Mitochondria | 1 | 2024 | 984 | 0.130 |
Why?
| | Interprofessional Relations | 1 | 2020 | 275 | 0.130 |
Why?
| | Parent-Child Relations | 2 | 2019 | 271 | 0.130 |
Why?
| | Emotional Adjustment | 1 | 2017 | 18 | 0.130 |
Why?
| | Erythrocytes | 1 | 2023 | 750 | 0.130 |
Why?
| | Anxiety Disorders | 2 | 2023 | 370 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 320 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 164 | 0.130 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 71 | 0.130 |
Why?
| | Linear Models | 1 | 2019 | 845 | 0.130 |
Why?
| | Diabetic Nephropathies | 1 | 2020 | 318 | 0.130 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 308 | 0.130 |
Why?
| | Analysis of Variance | 1 | 2019 | 1301 | 0.120 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 254 | 0.120 |
Why?
| | Suicide | 1 | 2024 | 725 | 0.120 |
Why?
| | Mental Health | 4 | 2026 | 792 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2019 | 545 | 0.120 |
Why?
| | Hemodynamics | 1 | 2021 | 1113 | 0.120 |
Why?
| | Students, Medical | 1 | 2021 | 374 | 0.120 |
Why?
| | Perception | 1 | 2018 | 376 | 0.120 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 557 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 905 | 0.110 |
Why?
| | Urologic Surgical Procedures | 1 | 2016 | 113 | 0.110 |
Why?
| | Adipose Tissue | 1 | 2020 | 643 | 0.110 |
Why?
| | Databases, Factual | 1 | 2021 | 1494 | 0.110 |
Why?
| | Hypopituitarism | 1 | 2015 | 16 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2019 | 479 | 0.110 |
Why?
| | Prognosis | 2 | 2020 | 4312 | 0.100 |
Why?
| | Pilot Projects | 1 | 2020 | 1886 | 0.100 |
Why?
| | United States | 7 | 2026 | 16018 | 0.100 |
Why?
| | Hospitalization | 1 | 2024 | 2446 | 0.100 |
Why?
| | Prevalence | 3 | 2025 | 2839 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5414 | 0.090 |
Why?
| | Depressive Disorder | 1 | 2015 | 386 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3329 | 0.090 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 6041 | 0.090 |
Why?
| | HLA Antigens | 1 | 2013 | 235 | 0.090 |
Why?
| | Cohort Studies | 4 | 2025 | 5957 | 0.080 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2022 | 66 | 0.080 |
Why?
| | Middle Aged | 4 | 2026 | 35971 | 0.070 |
Why?
| | Colorado | 1 | 2019 | 4558 | 0.070 |
Why?
| | Blood Glucose | 1 | 2019 | 2326 | 0.070 |
Why?
| | Phenotype | 3 | 2023 | 3147 | 0.070 |
Why?
| | Postoperative Complications | 2 | 2018 | 2950 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2873 | 0.070 |
Why?
| | Aged | 2 | 2025 | 25955 | 0.060 |
Why?
| | Emotions | 2 | 2022 | 578 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2021 | 2573 | 0.060 |
Why?
| | Postoperative Period | 2 | 2017 | 351 | 0.060 |
Why?
| | Glucose Clamp Technique | 1 | 2026 | 199 | 0.060 |
Why?
| | Autoantibodies | 1 | 2013 | 1505 | 0.060 |
Why?
| | XYY Karyotype | 1 | 2025 | 24 | 0.050 |
Why?
| | Sex Chromosome Disorders of Sex Development | 1 | 2025 | 17 | 0.050 |
Why?
| | Chromosomes, Human, X | 1 | 2025 | 76 | 0.050 |
Why?
| | Gonadoblastoma | 1 | 2024 | 7 | 0.050 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2024 | 28 | 0.050 |
Why?
| | Hypercalciuria | 1 | 2024 | 2 | 0.050 |
Why?
| | Psychotropic Drugs | 1 | 2025 | 77 | 0.050 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2024 | 3 | 0.050 |
Why?
| | Reference Values | 1 | 2025 | 794 | 0.050 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 2023 | 2 | 0.050 |
Why?
| | Vomiting | 1 | 2024 | 131 | 0.050 |
Why?
| | Cystatin C | 1 | 2023 | 66 | 0.050 |
Why?
| | Mutation | 3 | 2021 | 4081 | 0.050 |
Why?
| | Headache | 1 | 2024 | 151 | 0.050 |
Why?
| | Sex Chromosomes | 1 | 2023 | 53 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 147 | 0.050 |
Why?
| | Phosphates | 1 | 2024 | 177 | 0.050 |
Why?
| | Animals | 3 | 2021 | 37948 | 0.050 |
Why?
| | Virilism | 1 | 2022 | 6 | 0.050 |
Why?
| | Aneuploidy | 1 | 2023 | 90 | 0.050 |
Why?
| | Fever | 1 | 2024 | 313 | 0.050 |
Why?
| | Focus Groups | 1 | 2025 | 566 | 0.050 |
Why?
| | Counseling | 1 | 2025 | 405 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2024 | 297 | 0.040 |
Why?
| | Sex Differentiation | 1 | 2021 | 10 | 0.040 |
Why?
| | Menstrual Cycle | 1 | 2022 | 140 | 0.040 |
Why?
| | Creatinine | 1 | 2023 | 509 | 0.040 |
Why?
| | Body Weight | 1 | 2025 | 968 | 0.040 |
Why?
| | Hirsutism | 1 | 2021 | 11 | 0.040 |
Why?
| | Karyotype | 1 | 2021 | 19 | 0.040 |
Why?
| | Alopecia | 1 | 2021 | 37 | 0.040 |
Why?
| | Chromosomes, Human, Y | 1 | 2021 | 37 | 0.040 |
Why?
| | Mammary Glands, Human | 1 | 2021 | 68 | 0.040 |
Why?
| | Health Occupations | 1 | 2021 | 36 | 0.040 |
Why?
| | Mosaicism | 1 | 2021 | 73 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 287 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 17149 | 0.040 |
Why?
| | Uterus | 1 | 2021 | 224 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 323 | 0.040 |
Why?
| | Comorbidity | 1 | 2025 | 1652 | 0.040 |
Why?
| | Laparoscopy | 1 | 2024 | 477 | 0.040 |
Why?
| | Canada | 1 | 2021 | 432 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 2033 | 0.040 |
Why?
| | Proteomics | 1 | 2026 | 1183 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 88 | 0.040 |
Why?
| | Genitalia, Male | 1 | 2018 | 11 | 0.030 |
Why?
| | Minority Groups | 1 | 2020 | 283 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 233 | 0.030 |
Why?
| | Ovarian Neoplasms | 1 | 2024 | 589 | 0.030 |
Why?
| | Esthetics | 1 | 2018 | 50 | 0.030 |
Why?
| | Peer Group | 1 | 2020 | 256 | 0.030 |
Why?
| | Health Status | 1 | 2023 | 834 | 0.030 |
Why?
| | Universities | 1 | 2020 | 452 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1668 | 0.030 |
Why?
| | Social Media | 1 | 2020 | 167 | 0.030 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2017 | 32 | 0.030 |
Why?
| | Surgery, Plastic | 1 | 2018 | 53 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2847 | 0.030 |
Why?
| | Precision Medicine | 1 | 2020 | 454 | 0.030 |
Why?
| | Hormone Antagonists | 1 | 2016 | 31 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 355 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 890 | 0.030 |
Why?
| | Prejudice | 1 | 2016 | 61 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 650 | 0.030 |
Why?
| | Gonadal Dysgenesis, 46,XY | 1 | 2015 | 1 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1844 | 0.030 |
Why?
| | 46, XX Disorders of Sex Development | 1 | 2015 | 7 | 0.030 |
Why?
| | Karyotyping | 1 | 2015 | 105 | 0.030 |
Why?
| | Diabetes Insipidus | 1 | 2015 | 6 | 0.030 |
Why?
| | Holoprosencephaly | 1 | 2015 | 8 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 381 | 0.030 |
Why?
| | Human Growth Hormone | 1 | 2015 | 46 | 0.030 |
Why?
| | Thyrotropin | 1 | 2015 | 119 | 0.030 |
Why?
| | Hypogonadism | 1 | 2015 | 90 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 255 | 0.030 |
Why?
| | Sleep | 1 | 2021 | 890 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2137 | 0.020 |
Why?
| | Curriculum | 1 | 2021 | 1063 | 0.020 |
Why?
| | WT1 Proteins | 1 | 2012 | 12 | 0.020 |
Why?
| | SOX9 Transcription Factor | 1 | 2012 | 27 | 0.020 |
Why?
| | Incidence | 1 | 2019 | 2892 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 11735 | 0.020 |
Why?
| | RNA Splicing Factors | 1 | 2012 | 66 | 0.020 |
Why?
| | Genetic Testing | 1 | 2015 | 480 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 552 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 949 | 0.020 |
Why?
| | Depression | 1 | 2020 | 1561 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2922 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2365 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 7122 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3729 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2012 | 906 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2934 | 0.020 |
Why?
| | Mass Screening | 1 | 2015 | 1348 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1484 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1726 | 0.010 |
Why?
| | Mice | 1 | 2021 | 18261 | 0.010 |
Why?
|
|
Nokoff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|